Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAHARA: Subcutaneous C1 Esterase Inhibitor for HAE
NCT02584959Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2015
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of C1 esterase inhibitor human in hereditary angioedema (HAE), sponsored by Takeda. Started Nov 2015; status: completed.
02
Drugs
C1 esterase inhibitor human
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT02584959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02584959.